| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England journal of medicine 359 (4), 378-390, 2008 | 15645 | 2008 |
| Cabozantinib in patients with advanced and progressing hepatocellular carcinoma GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ... New England Journal of Medicine 379 (1), 54-63, 2018 | 2346 | 2018 |
| Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. T Livraghi, A Giorgio, G Marin, A Salmi, I De Sio, L Bolondi, M Pompili, ... Radiology 197 (1), 101-108, 1995 | 1275 | 1995 |
| Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)-update 2008 M Claudon, D Cosgrove, T Albrecht, L Bolondi, M Bosio, F Calliada, ... Ultraschall in der Medizin-European Journal of Ultrasound 29 (01), 28-44, 2008 | 1274 | 2008 |
| Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial J Bruix, T Takayama, V Mazzaferro, GY Chau, J Yang, M Kudo, J Cai, ... The lancet oncology 16 (13), 1344-1354, 2015 | 1120 | 2015 |
| Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals F Conti, F Buonfiglioli, A Scuteri, C Crespi, L Bolondi, P Caraceni, ... Journal of hepatology 65 (4), 727-733, 2016 | 1071 | 2016 |
| Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma L Gramantieri, M Ferracin, F Fornari, A Veronese, S Sabbioni, CG Liu, ... Cancer research 67 (13), 6092-6099, 2007 | 1063 | 2007 |
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ... Journal of hepatology 57 (4), 821-829, 2012 | 952 | 2012 |
| Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis L Bolondi, S Sofia, S Siringo, S Gaiani, A Casali, G Zironi, F Piscaglia, ... Gut 48 (2), 251-259, 2001 | 873 | 2001 |
| MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma F Fornari, L Gramantieri, M Ferracin, A Veronese, S Sabbioni, GA Calin, ... Oncogene 27 (43), 5651-5661, 2008 | 837 | 2008 |
| Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions L Bolondi, A Burroughs, JF Dufour, PR Galle, V Mazzaferro, F Piscaglia, ... Seminars in liver disease 32 (04), 348-359, 2012 | 758 | 2012 |
| Guidelines for the use of contrast agents in ultrasound-january 2004 T Albrecht, M Blomley, L Bolondi, M Claudon, JM Correas, D Cosgrove, ... Ultraschall in der Medizin-European Journal of Ultrasound 25 (04), 249-256, 2004 | 754 | 2004 |
| The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations F Piscaglia, L Bolondi Ultrasound in medicine & biology 32 (9), 1369-1375, 2006 | 707 | 2006 |
| Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization JL Raoul, B Sangro, A Forner, V Mazzaferro, F Piscaglia, L Bolondi, ... Cancer treatment reviews 37 (3), 212-220, 2011 | 682 | 2011 |
| Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma R Golfieri, E Giampalma, M Renzulli, R Cioni, I Bargellini, C Bartolozzi, ... British journal of cancer 111 (2), 255-264, 2014 | 656 | 2014 |
| Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis S Leoni, F Tovoli, L Napoli, I Serio, S Ferri, L Bolondi World journal of gastroenterology 24 (30), 3361, 2018 | 654 | 2018 |
| Measurement of gastric emptying time by real-time ultrasonography L Bolondi, M Bortolotti, V Santi, T Calletti, S Gaiani, G Labò Gastroenterology 89 (4), 752-759, 1985 | 605 | 1985 |
| Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence JL Raoul, A Forner, L Bolondi, TT Cheung, R Kloeckner, T de Baere Cancer treatment reviews 72, 28-36, 2019 | 588 | 2019 |
| Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients T Livraghi, L Bolondi, S Lazzaroni, G Marin, A Morabito, GL Rapaccini, ... Cancer 69 (4), 925-929, 1992 | 584 | 1992 |
| Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival L Barbara, G Benzi, S Gaiani, F Fusconi, G Zironi, S Siringo, A Rigamonti, ... Hepatology 16 (1), 132-137, 1992 | 575 | 1992 |